logo
Plus   Neg
Share
Email

E.W. Scripps Posts Loss In Q3 - Quick Facts

The E.W. Scripps Company (SSP) reported a loss per share from continuing operations of $0.27 for the third quarter of 2019 compared to profit of $0.24 per share, prior year. On average, seven analysts polled by Thomson Reuters expected the company to report a loss per share of $0.12, for the quarter. Analysts' estimates typically exclude special items. The company noted that pre-tax costs for the current quarter included $16.7 million of acquisition and related integration costs that increased the loss by 16 cents per share.

Third-quarter operating revenues increased to $349.78 million from $302.73 million, prior year. Analysts expected revenue of $342.78 million, for the quarter. Revenue from Local Media was $252 million, up 9.4 percent from the prior-year quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
RELATED NEWS
Follow RTT